Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation

Autor:	H Löffler, Gerald Holtmann, Stefan Müller-Lissner, Peter C. Rueegg, G Weidinger
Rok vydání:	2005
Předmět:	Adult Male Continuous therapy medicine.medical_specialty Indoles Constipation Tegaserod Adolescent Gastroenterology Irritable Bowel Syndrome Gastrointestinal Agents Recurrence Internal medicine medicine Humans Pharmacology (medical) Adverse effect Irritable bowel syndrome Retrospective Studies Gastrointestinal agent Hepatology business.industry Retrospective cohort study Middle Aged medicine.disease Treatment Outcome Tolerability Retreatment Female medicine.symptom business medicine.drug
Zdroj:	Alimentary Pharmacology and Therapeutics. 21:11-20
ISSN:	1365-2036 0269-2813
DOI:	10.1111/j.1365-2036.2004.02294.x
Popis:	Summary Background : Symptoms of irritable bowel syndrome are often cyclical and thus may require repeated rather than continuous therapy. Tegaserod is effective and well-tolerated for irritable bowel syndrome with constipation but data on retreatment are lacking. Aim : To assess whether tegaserod retreatment is as efficacious and well-tolerated as initial treatment in a primary care setting. Methods : This open-label trial was designed to evaluate the effectiveness of tegaserod under real-life conditions. Irritable bowel syndrome with constipation patients received tegaserod 6 mg b.d. for 12 weeks; response was assessed at weeks 4 and 12. Responders (those achieving satisfactory relief for at least 2 of the previous 4 weeks) at weeks 4 and/or 12 entered an 8-week withdrawal period where symptom recurrence was assessed. Patients experiencing recurrence could receive tegaserod 6 mg b.d. for another 4 weeks (retreatment phase) and on completion, could choose to continue tegaserod in a 6-month extension study. Results : A total of 513 patients received initial treatment with tegaserod; 85.0% (436 of 513) responded. 403 responders entered the withdrawal period; symptoms recurred in 83.9% (338 of 403) after a mean of 38 days. Of the 307 patients who subsequently entered retreatment 89.3% (274 of 307) responded. Among patients entering the retreatment period, 269 (87.6%) had responded within the first 4 weeks of initial treatment. Of these, 243 (90.3%) responded to tegaserod retreatment. Adverse events were infrequent and similar during 4 weeks of the initial treatment period (11.1%) and on retreatment (10.4%). The extension study, completed by 188 of 232 (81.0%) patients, demonstrated good long-term tolerability of tegaserod. Conclusions : Irritable bowel syndrome with constipation patients can be successfully treated, and retreated, with tegaserod 6 mg b.d. Tegaserod was well-tolerated during initial and retreatment periods.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43c2d250c0867a07266e24ffb3f932da https://doi.org/10.1111/j.1365-2036.2004.02294.x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.